Download fulltext
HTML
Nemati, M., Danesh Pouya, F., Roshani Asl, E., & Rasmi, Y. (2023). BAY 11-7082: An Anti-inflammatory Drug for COVID-19. Sudan Journal of Medical Sciences (SJMS), 18(1), 117–120. https://doi.org/10.18502/sjms.v18i1.12872
https://doi.org/10.18502/sjms.v18i1.12872
statistics
- 349 Abstract Views
- 222 PDF Views
- 0 HTML Views
authors
-
Mohadeseh Nemati
Mohadeseh Nemati
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
-
Fahima Danesh Pouya
Fahima Danesh Pouya
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
-
Elmira Roshani Asl
Elmira Roshani Asl
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
-
Yousef Rasmi
Yousef Rasmi
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Published Date
- Mar 31, 2023
BAY 11-7082: An Anti-inflammatory Drug for COVID-19
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus named by the International Committee on Taxonomy of Viruses. COVID-19 patients have high mortality due to respiratory failure from acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2. The abnormal activation of P21-activated kinase (PAK1, RAC/CDC42-activated kinase 1) is reported in COVID-19. The PAK1 induces nuclear factor kappa B (NF-κB) activation as well as inflammatory pathways through its stimulation. BAY 11-7082 {(E) 3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile is one of the therapies that inhibit inflammation via mentioned signaling pathway, therefore, we suggest that this drug can potentially be effective in treating COVID-19.
Keywords:
BAY 11-7082, COVID-19, PAK1
References
[1] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M.,…Cao, B. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506.
[2] Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine, 27(2), taaa021.
[3] Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine, 46(5), 846–848.
[4] Maruta, H. (2014). Herbal therapeutics that block the oncogenic kinase PAK1: A practical approach towards PAK1‐dependent diseases and longevity. Phytotherapy Research, 28(5), 656–672.
[5] Maruta, H., & He, H. (2020). PAK1-blockers: Potential therapeutics against COVID-19. Medicine in Drug Discovery, 6, 100039.
[6] Dammann, K., Khare, V., & Gasche, C. (2014). Tracing PAKs from GI inflammation to cancer. Gut, 63(7), 1173–1184.
[7] Bowie, A., & O’Neill, L. A. (2000). Oxidative stress and nuclear factor-κB activation: A reassessment of the evidence in the light of recent discoveries. Biochemical Pharmacology, 59(1), 13–23.
[8] Tedgui, A., & Mallat, Z. (2001). Anti-inflammatory mechanisms in the vascular wall. Circulation Research, 88(9), 877–887.
[9] Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997). Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Journal of Biological Chemistry, 272(34), 21096–21103.
[10] Malladi, V., Puthenedam, M., Williams, P. H., & Balakrishnan, A. (2004). Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-κB and MAP kinases. Inflammation, 28(6), 345–353.
[11] Xue, W., Meylan, E., Oliver, T. G., Feldser, D. M., Winslow, M. M., Bronson, R., & Jacks, T. (2011). Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discovery, 1(3), 236–247.
[12] Strickson, S., Campbell, D. G., Emmerich, C. H., Knebel, A., Plater, L., Ritorto, M. S., Shpiro, N., & Cohen, P. (2013). The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochemical Journal, 451(3), 427–437.
[13] Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., & Alnemri, E. S. (2010). Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. Journal of Biological Chemistry, 285(13), 9792–9802.
[14] Martinon, F., Mayor, A., & Tschopp, J. (2009). The inflammasomes: Guardians of the body. Annual Review of Immunology, 27, 229–265.
[15] Dinarello, C. A. (1998). Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β converting enzyme. Annals of the New York Academy of Sciences, 856(1), 1–11.
[16] Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology, 27, 519–550.
[17] Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology, 9(8), 847.
[2] Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine, 27(2), taaa021.
[3] Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine, 46(5), 846–848.
[4] Maruta, H. (2014). Herbal therapeutics that block the oncogenic kinase PAK1: A practical approach towards PAK1‐dependent diseases and longevity. Phytotherapy Research, 28(5), 656–672.
[5] Maruta, H., & He, H. (2020). PAK1-blockers: Potential therapeutics against COVID-19. Medicine in Drug Discovery, 6, 100039.
[6] Dammann, K., Khare, V., & Gasche, C. (2014). Tracing PAKs from GI inflammation to cancer. Gut, 63(7), 1173–1184.
[7] Bowie, A., & O’Neill, L. A. (2000). Oxidative stress and nuclear factor-κB activation: A reassessment of the evidence in the light of recent discoveries. Biochemical Pharmacology, 59(1), 13–23.
[8] Tedgui, A., & Mallat, Z. (2001). Anti-inflammatory mechanisms in the vascular wall. Circulation Research, 88(9), 877–887.
[9] Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997). Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Journal of Biological Chemistry, 272(34), 21096–21103.
[10] Malladi, V., Puthenedam, M., Williams, P. H., & Balakrishnan, A. (2004). Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-κB and MAP kinases. Inflammation, 28(6), 345–353.
[11] Xue, W., Meylan, E., Oliver, T. G., Feldser, D. M., Winslow, M. M., Bronson, R., & Jacks, T. (2011). Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discovery, 1(3), 236–247.
[12] Strickson, S., Campbell, D. G., Emmerich, C. H., Knebel, A., Plater, L., Ritorto, M. S., Shpiro, N., & Cohen, P. (2013). The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochemical Journal, 451(3), 427–437.
[13] Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., & Alnemri, E. S. (2010). Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. Journal of Biological Chemistry, 285(13), 9792–9802.
[14] Martinon, F., Mayor, A., & Tschopp, J. (2009). The inflammasomes: Guardians of the body. Annual Review of Immunology, 27, 229–265.
[15] Dinarello, C. A. (1998). Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β converting enzyme. Annals of the New York Academy of Sciences, 856(1), 1–11.
[16] Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology, 27, 519–550.
[17] Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology, 9(8), 847.